“Our team has demonstrated the presence of SETDB1 abnormalities, particularly its amplification, through WES analysis of osteosarcoma human samples and cell lines” “Our team has demonstrated the ...
SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment ...
A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.” Authors ...
Kazia Therapeutics Limited, a clinical-stage oncology company advancing therapies to reprogramme cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results